• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Tofacitinib effective as induction and maintenance therapy for ulcerative colitis

byAndrew Cheung, MD MBAandDayton McMillan
May 9, 2017
in Chronic Disease, Gastroenterology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with active ulcerative colitis who failed prior treatment achieved significantly greater remission of disease and mucosal healing compared to those treated with placebo.

2. Remission of ulcerative colitis symptoms over 1 year was significantly greater for patients who initially responded to tofacitinib and continued therapy compared to patients who responded and then were treated with a placebo.

Evidence Rating: 1 (Excellent)

Study Rundown:  Ulcerative colitis is an inflammatory condition of the colon. The condition is difficult to treat despite an array of therapies available. Janus kinase (JAK) receptors are involved in many intracellular immune pathways associated with inflammatory bowel disease, therefore JAK inhibitors may prove useful in treatment of ulcerative colitis. Prior phase 2 trials indicated tofacitinib, a JAK inhibitor, can induce remission of ulcerative colitis. In three phase 3 trials, tofacitinib was further evaluated as an induction and maintenance treatment for patients with ulcerative colitis.

The studies randomized patients with moderate to severe active ulcerative colitis into treatment and placebo groups. In the first 2 studies (OCTAVE 1 and 2), patients received 10 mg of tofacitinib twice a day or a placebo for 8 weeks. At 8 weeks, treated patients were significantly more likely to have achieved remission and gastrointestinal mucosal healing than those treated with placebo. For the third trial (OCTAVE Sustain), patients who responded to tofacitinib were randomized to receive 5 mg tofacitinib, 10 mg tofacitinib, or a placebo twice a day. At 1 year, patients receiving either treatment dose were significantly more likely than those treated with placebo to still be in remission and have mucosal healing.

Click to read the study, published today in NEJM

Relevant Reading: Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)

RELATED REPORTS

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis

Ozanimod effective for induction and maintenance therapy of ulcerative colitis

In-Depth [randomized controlled trial]: This work describes the results of three separate, multinational, randomized controlled trials carried out from 2012 to 2016. All trials included adult patients with a confirmed diagnosis of ulcerative colitis defined as moderate to severe as assessed by the Mayo score, which included pre- and post-treatment endoscopy. All patients included had to have failed prior treatment for ulcerative colitis, and were generally not allowed to be on other ulcerative colitis treatments during the trial. The first two trials (OCTAVE 1 and 2) randomly assigned patients to treatment groups of 10 mg tofacitinib twice a day (n = 476 and 439, respectively) or a placebo (n = 122 and 112, respectively) for 8 weeks. Key endpoints were remission and mucosal healing at 8 weeks, both assessed by Mayo scores. At 8 weeks, patients in OCTAVE 1 and 2 trials treated with tofacitinib experienced remission significantly more than those in the placebo groups (OCATVE 1 – 18.5% vs 8.2%, p = 0.007; OCTAVE 2 – 16.6% vs 3.6%, p < 0.001). Mucosal healing was also more common in the treatment groups compared to the placebo groups (31.3% vs 15.6%, p < 0.001; 28.4% vs 11.6%, p < 0.001; respectively).

In the OCTAVE Sustain trail, patients who responded to tofacitinib were randomized to receive maintenance therapy over 52 weeks with 5 mg tofacitinib (n = 198), 10 mg tofacitinib (n = 197), or placebo (n=198) twice a day. Their study endpoints were also remission and mucosal healing. At 52 weeks, patients in either the 5 mg or 10 mg tofacitinib groups were more likely to be in remission (34.3% and 40.6%, respectively) than those treated with placebo (11.1%, p < 0.001 for both comparisons with placebo group). Mucosal healing was also more common in the treated groups (37.4% and 45.7%, respectively) compared to the placebo group (13.1%, p < 0.001 for both comparisons with placebo group). In the OCTAVE Sustain trial, adverse events occurred in the 5 mg, 10 mg, and placebo groups at rates of 72.2%, 79.6%, and 75.3%, respectively. The most frequent adverse events, besides worsening ulcerative colitis, were nasopharyngitis, arthralgia, and headache.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: JAK kinaseUlcerative Colitis
Previous Post

2 Minute Medicine Rewind May 8, 2017

Next Post

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

RelatedReports

Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis

June 14, 2022
Patient Basics: Ulcerative Colitis
Chronic Disease

Ozanimod effective for induction and maintenance therapy of ulcerative colitis

November 3, 2021
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis

July 9, 2021
Next Post
Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

PCSK9 inhibitor significantly reduces the risk of cardiovascular events: The FOURIER trial

Use of plant-based therapies and menopausal symptoms

Antibiotics often overprescribed in elderly patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ciprofol comparable to propofol for general anesthesia induction for gynecological surgery
  • Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
  • Type of compensation model influences gender pay gap in primary care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.